Quick Answer
Celldex Therapeutics, Inc. reported Operating Income Loss of -$287.37 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed a decrease of -47.3% in Operating Income Loss from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Celldex Therapeutics, Inc.'s Operating Income Loss has declined by 679.8%.
- Historical annual values: Fiscal year 2025: -$287.37 million | Fiscal year 2024: -$195.08 million | Fiscal year 2023: -$154.54 million | Fiscal year 2022: -$115.23 million | Fiscal year 2021: -$71.24 million | Fiscal year 2020: -$63.35 million | Fiscal year 2019: -$55.03 million | Fiscal year 2018: -$156.44 million | Fiscal year 2017: -$121.53 million | Fiscal year 2016: -$132.92 million | Fiscal year 2015: -$129.54 million | Fiscal year 2014: -$122.43 million | Fiscal year 2013: -$81.44 million | Fiscal year 2012: -$58.08 million | Fiscal year 2011: -$43.40 million | Fiscal year 2010: -$6.46 million | Fiscal year 2009: -$36.85 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: